Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
245 Development and application of physiologically based pharmacokinetic – pharmacodynamic (PBPK-PD) model for dose optimization of TAK-102: GPC3 targeted CAR-T armored with IL-7 and CCL-19
Compose a Response to This Article
Other responses
No responses have been published for this article.
